アデノ随伴ウイルス
引用文献

↑  Russel DW, Deyle DR (2010). “Adeno- associated virus vector integration”. Current Opinion in Molecular Therapy 11 (4):  442-447. PMC 2929125. PMID 19649989. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2929125/.
↑  Grieger JC, Samulski RJ (2005). “Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications”. Advances in Biochemical Engineering/biotechnology. Advances in Biochemical Engineering/Biotechnology 99:  119?45. doi:10.1007/10_005. ISBN 3-540-28404-4. PMID 16568890.
↑  Kotin RM, Siniscalco M, Samulski RJ, et al. (1 March 1990). “Site-specific integration by adeno-associated virus”. Proc Natl Acad Sci U S A 87 (6):  2211–5. doi:10.1073/pnas.87.6.2211. PMC 53656. PMID 2156265. http://www.pnas.org/content/87/6/2211.full.pdf+html?sid=b3e80d13-02c4-437f-95f7-a9032aaacb2a.
↑  Surosky RT, Urabe M, Godwin SG, et al. (1 October 1997). “Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome”. Journal of Virology 71 (10):  7951–9. PMC 192153. PMID 9311886. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=9311886.
↑  Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J (September 1999). “Immune responses to adenovirus and adeno-associated virus in humans”. Gene Therapy 6 (9):  1574–83. doi:10.1038/sj.gt.3300994. PMID 10490767.
↑  Hernandez YJ, Wang J, Kearns WG, Loiler S, Poirier A, Flotte TR (1 October 1999). “Latent Adeno-Associated Virus Infection Elicits Humoral but Not Cell-Mediated Immune Responses in a Nonhuman Primate Model”. Journal of Virology 73 (10):  8549–58. PMC 112875. PMID 10482608. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=10482608.
↑  Ponnazhagan S, Mukherjee P, Yoder MC, et al. (April 1997). “Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice”. Gene 190 (1):  203–10. doi:10.1016/S0378-1119(96)00576-8. PMID 9185868.
↑  McCarty, D M; Monahan, P E; Samulski, R J (2001). “Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis”. Gene Therapy 8 (16):  1248–54. doi:10.1038/sj.gt.3301514. PMID 11509958.
↑  Rogers GL (Jan 2014). “Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B..”. J Transl Med. 12. doi:10.1186/1479-5876-12-25. PMC 3904690. PMID 24460861. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904690/.
↑  J. of Gene Medicine, http://www.abedia.com/wiley/vectors.php
↑  Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis The New England journal of medicine, 358(21), 2240–2248. doi:10.1056/NEJMoa0802315
↑  Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., et al. (2008). Effect of gene therapy on visual function in Leber's congenital amaurosis The New England journal of medicine, 358(21), 2231–2239. doi:10.1056/NEJMoa0802268 PMID 18441371
↑  Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., et al. (2008). Treatment of Leber Congenital Amaurosis Due to RPE65Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial. Human gene therapy, 19(10), 979–990. doi:10.1089/hum.2008.107 PMID 18774912
↑  Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B The New England journal of medicine, 365(25), 2357–2365. doi:10.1056/NEJMoa1108046
↑  Jessup, M; Greenberg B, Mancini DM, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo K, Dittrich H, Hajjar, RJ (June 2011). “Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure”. Circulation 124 (3):  304–313. doi:10.1161/CIRCULATIONAHA.111.022889. ISSN 1524-4539. PMID 21709064. http://circ.ahajournals.org/content/124/3/304.long 2012年3月24日閲覧。.
↑  LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., et al. (2011). AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. The Lancet Neurology, 10(4), 309–319. doi:10.1016/S1474-4422(11)70039-4 PMID 21419704
1 2  Carter BJ (May 2005). “Adeno-associated virus vectors in clinical trials”. Human Gene Therapy 16 (5):  541?50. doi:10.1089/hum.2005.16.541. PMID 15916479.
↑  Kaplitt MG, Feigin A, Tang C, et al. (June 2007). “Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial”. Lancet 369 (9579):  2097?105. doi:10.1016/S0140-6736(07)60982-9. PMID 17586305.
↑  Erles K, Rohde V, Thaele M, Roth S, Edler L, Schlehofer JR (November 2001). “DNA of adeno-associated virus (AAV) in testicular tissue and in abnormal semen samples”. Human Reproduction 16 (11):  2333–7. doi:10.1093/humrep/16.11.2333. PMID 11679515.
↑  Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouzé E, Pilati C, Verret B, Blanc JF, Balabaud C, Calderaro J, Laurent A, Letexier M, Bioulac-Sage P, Calvo F, Zucman-Rossi J. "Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas" Nat Genet. 2015 Oct;47(10):1187-93. doi:10.1038/ng.3389. Epub 2015 Aug 24. PMID 26301494
↑  Carter, BJ (2000). “Adeno-associated virus and adeno-associated virus vectors for gene delivery”. In DD Lassic & N Smyth Templeton. Gene Therapy: Therapeutic Mechanisms and Strategies. New York City: Marcel Dekker, Inc.. pp. 41–59. ISBN 0-585-39515-2
↑  Bohenzky RA, LeFebvre RB, Berns KI (October 1988). “Sequence and symmetry requirements within the internal palindromic sequences of the adeno-associated virus terminal repeat”. Virology 166 (2):  316–27. doi:10.1016/0042-6822(88)90502-8. PMID 2845646.
↑  Wang XS, Ponnazhagan S, Srivastava A (July 1995). “Rescue and replication signals of the adeno-associated virus 2 genome”. Journal of Molecular Biology 250 (5):  573–80. doi:10.1006/jmbi.1995.0398. PMID 7623375.
1 2  Weitzman MD, Kyöstiö SR, Kotin RM, Owens RA (June 1994). “Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA”. Proceedings of the National Academy of Sciences of the United States of America 91 (13):  5808–12. doi:10.1073/pnas.91.13.5808. PMC 44086. PMID 8016070. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC44086/.
↑  Zhou X, Muzyczka N (April 1, 1998). “In vitro packaging of adeno-associated virus DNA”. Journal of Virology 72 (4):  3241–7. PMC 109794. PMID 9525651. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=9525651.
↑  Nony P, Tessier J, Chadeuf G, et al. (October 2001). “Novel cis-acting replication element in the adeno-associated virus type 2 genome is involved in amplification of integrated rep-cap sequences”. Journal of Virology 75 (20):  9991–4. doi:10.1128/JVI.75.20.9991-9994.2001. PMC 114572. PMID 11559833. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114572/.
↑  Nony P, Chadeuf G, Tessier J, Moullier P, Salvetti A (January 2003). “Evidence for packaging of rep-cap sequences into adeno-associated virus (AAV) type 2 capsids in the absence of inverted terminal repeats: a model for generation of rep-positive AAV particles”. Journal of Virology 77 (1):  776–81. doi:10.1128/JVI.77.1.776-781.2003. PMC 140600. PMID 12477885. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC140600/.
↑  Philpott NJ, Giraud-Wali C, Dupuis C, et al. (June 2002). “Efficient integration of recombinant adeno-associated virus DNA vectors requires a p5-rep sequence in cis”. Journal of Virology 76 (11):  5411–21. doi:10.1128/JVI.76.11.5411-5421.2002. PMC 137060. PMID 11991970. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137060/.
↑  Tullis GE, Shenk T (December 2000). “Efficient replication of adeno-associated virus type 2 vectors: a cis-acting element outside of the terminal repeats and a minimal size”. Journal of Virology 74 (24):  11511–21. doi:10.1128/JVI.74.24.11511-11521.2000. PMC 112431. PMID 11090148. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC112431/.
1 2  Kyöstiö SR, Owens RA, Weitzman MD, Antoni BA, Chejanovsky N, Carter BJ (May 1, 1994). “Analysis of adeno-associated virus (AAV) wild-type and mutant Rep proteins for their abilities to negatively regulate AAV p5 and p19 mRNA levels”. Journal of Virology 68 (5):  2947–57. PMC 236783. PMID 8151765. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=8151765.
↑  Im DS, Muzyczka N (May 1990). “The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity”. Cell 61 (3):  447–57. doi:10.1016/0092-8674(90)90526-K. PMID 2159383.
↑  Im DS, Muzyczka N (February 1, 1992). “Partial purification of adeno-associated virus Rep78, Rep52, and Rep40 and their biochemical characterization”. Journal of Virology 66 (2):  1119–28. PMC 240816. PMID 1309894. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=1309894.
↑  Samulski RJ (2003). “AAV vectors, the future workhorse of human gene therapy”. Ernst Schering Research Foundation Workshop (43):  25–40. PMID 12894449.
↑  Trempe JP, Carter BJ (January 1, 1988). “Regulation of adeno-associated virus gene expression in 293 cells: control of mRNA abundance and translation”. Journal of Virology 62 (1):  68–74. PMC 250502. PMID 2824856. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=2824856.
↑  Jay FT, Laughlin CA, Carter BJ (May 1981). “Eukaryotic translational control: adeno-associated virus protein synthesis is affected by a mutation in the adenovirus DNA-binding protein”. Proceedings of the National Academy of Sciences of the United States of America 78 (5):  2927–31. doi:10.1073/pnas.78.5.2927. PMC 319472. PMID 6265925. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC319472/.
↑  Becerra SP, Rose JA, Hardy M, Baroudy BM, Anderson CW (December 1985). “Direct mapping of adeno-associated virus capsid proteins B and C: a possible ACG initiation codon”. Proceedings of the National Academy of Sciences of the United States of America 82 (23):  7919–23. doi:10.1073/pnas.82.23.7919. PMC 390881. PMID 2999784. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC390881/.
↑  Cassinotti P, Weitz M, Tratschin JD (November 1988). “Organization of the adeno-associated virus (AAV) capsid gene: mapping of a minor spliced mRNA coding for virus capsid protein 1”. Virology 167 (1):  176–84. doi:10.1016/0042-6822(88)90067-0. PMID 2847413.
1 2  Muralidhar S, Becerra SP, Rose JA (January 1, 1994). “Site-directed mutagenesis of adeno-associated virus type 2 structural protein initiation codons: effects on regulation of synthesis and biological activity”. Journal of Virology 68 (1):  170–6. PMC 236275. PMID 8254726. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=8254726.
↑  Trempe JP, Carter BJ (September 1, 1988). “Alternate mRNA splicing is required for synthesis of adeno-associated virus VP1 capsid protein”. Journal of Virology 62 (9):  3356–63. PMC 253458. PMID 2841488. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=2841488.
↑  Rabinowitz JE, Samulski RJ (December 2000). “Building a better vector: the manipulation of AAV virions”. Virology 278 (2):  301–8. doi:10.1006/viro.2000.0707. PMID 11118354.
↑  Girod A, Wobus CE, Zádori Z, et al. (May 1, 2002). “The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity”. The Journal of General Virology 83 (Pt 5):  973–8. PMID 11961250. http://vir.sgmjournals.org/cgi/pmidlookup?view=long&pmid=11961250.
↑  Warrington KH, Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S, Muzyczka N (June 2004). “Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus”. Journal of Virology 78 (12):  6595–609. doi:10.1128/JVI.78.12.6595-6609.2004. PMC 416546. PMID 15163751. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC416546/.
↑  Xie Q, Bu W, Bhatia S, et al. (August 2002). “The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy”. Proceedings of the National Academy of Sciences of the United States of America 99 (16):  10405–10. doi:10.1073/pnas.162250899. PMC 124927. PMID 12136130. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC124927/.
↑  Mori S, Wang L, Takeuchi T, Kanda T (December 2004). “Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein”. Virology 330 (2):  375–83. doi:10.1016/j.virol.2004.10.012. PMID 15567432.
1 2  Bartlett JS, Samulski RJ, McCown TJ (May 1998). “Selective and rapid uptake of adeno-associated virus type 2 in brain”. Human Gene Therapy 9 (8):  1181–6. doi:10.1089/hum.1998.9.8-1181. PMID 9625257.
↑  Fischer AC, Beck SE, Smith CI, et al. (December 2003). “Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques”. Molecular Therapy 8 (6):  918–26. doi:10.1016/j.ymthe.2003.08.015. PMID 14664794.
↑  Nicklin SA, Buening H, Dishart KL, et al. (September 2001). “Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells”. Molecular Therapy 4 (3):  174–81. doi:10.1006/mthe.2001.0424. PMID 11545607.
↑  Rabinowitz JE, Xiao W, Samulski RJ (December 1999). “Insertional mutagenesis of AAV2 capsid and the production of recombinant virus”. Virology 265 (2):  274–85. doi:10.1006/viro.1999.0045. PMID 10600599.
↑  Shi W, Bartlett JS (April 2003). “RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism”. Molecular Therapy 7 (4):  515–25. doi:10.1016/S1525-0016(03)00042-X. PMID 12727115.
↑  Wu P, Xiao W, Conlon T, et al. (September 2000). “Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism”. Journal of Virology 74 (18):  8635–47. doi:10.1128/JVI.74.18.8635-8647.2000. PMC 102071. PMID 10954565. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC102071/.
↑  Manno CS, Chew AJ, Hutchison S, et al. (April 2003). “AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B”. Blood 101 (8):  2963–72. doi:10.1182/blood-2002-10-3296. PMID 12515715.
↑  Richter M, Iwata A, Nyhuis J, et al. (April 2000). “Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo”. Physiological Genomics 2 (3):  117–27. PMID 11015590.
↑  Koeberl DD, Alexander IE, Halbert CL, Russell DW, Miller AD (February 1997). “Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors”. Proceedings of the National Academy of Sciences of the United States of America 94 (4):  1426–31. doi:10.1073/pnas.94.4.1426. PMC 19807. PMID 9037069. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC19807/.
↑  Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A (January 1999). “Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2”. Nature Medicine 5 (1):  71–7. doi:10.1038/4758. PMID 9883842.
↑  Summerford C, Samulski RJ (February 1, 1998). “Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions”. Journal of Virology 72 (2):  1438–45. PMC 124624. PMID 9445046. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=9445046.
↑  Summerford C, Bartlett JS, Samulski RJ (January 1999). “AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection”. Nature Medicine 5 (1):  78–82. doi:10.1038/4768. PMID 9883843.
↑  Qiu J, Handa A, Kirby M, Brown KE (March 2000). “The interaction of heparin sulfate and adeno-associated virus 2”. Virology 269 (1):  137–47. doi:10.1006/viro.2000.0205. PMID 10725206.
↑  Pajusola K, Gruchala M, Joch H, Lüscher TF, Ylä-Herttuala S, Büeler H (November 2002). “Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells”. Journal of Virology 76 (22):  11530–40. doi:10.1128/JVI.76.22.11530-11540.2002. PMC 136795. PMID 12388714. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC136795/.
↑  “Common virus 'kills cancer'”. CNN. (6月22日2005年). https://edition.cnn.com/2005/HEALTH/06/22/cancer.virus/index.html 8月5日2009年閲覧。
↑  http://www.fred.psu.edu/ds/retrieve/fred/investigator/cmm10
↑  Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM (September 2002). “Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy”. Proceedings of the National Academy of Sciences of the United States of America 99 (18):  11854–9. doi:10.1073/pnas.182412299. PMC 129358. PMID 12192090. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC129358/.
1 2  Halbert CL, Allen JM, Miller AD (July 2001). “Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors”. Journal of Virology 75 (14):  6615–24. doi:10.1128/JVI.75.14.6615-6624.2001. PMC 114385. PMID 11413329. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114385/.
1 2  Rabinowitz JE, Bowles DE, Faust SM, Ledford JG, Cunningham SE, Samulski RJ (May 2004). “Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups”. Journal of Virology 78 (9):  4421–32. doi:10.1128/JVI.78.9.4421-4432.2004. PMC 387689. PMID 15078923. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC387689/.
↑  Chen S, Kapturczak M, Loiler SA, et al. (February 2005). “Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors”. Human Gene Therapy 16 (2):  235–47. doi:10.1089/hum.2005.16.235. PMC 1364465. PMID 15761263. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1364465/.
↑  Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA (August 2001). “Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity”. Journal of Virology 75 (15):  6884–93. doi:10.1128/JVI.75.15.6884-6893.2001. PMC 114416. PMID 11435568. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114416/.
↑  Di Pasquale G, Davidson BL, Stein CS, et al. (October 2003). “Identification of PDGFR as a receptor for AAV-5 transduction”. Nature Medicine 9 (10):  1306–12. doi:10.1038/nm929. PMID 14502277.
↑  Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, Muruve DA (May 2002). “Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors”. Journal of Virology 76 (9):  4580–90. doi:10.1128/JVI.76.9.4580-4590.2002. PMC 155101. PMID 11932423. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC155101/.
1 2  Zaiss AK, Muruve DA (June 2005). “Immune responses to adeno-associated virus vectors”. Current Gene Therapy 5 (3):  323–31. doi:10.2174/1566523054065039. PMID 15975009.
1 2 3  Madsen, D.; Cantwell, E.R.; O'Brien, T.; Johnson, P.A.; Mahon, B.P. (2009), “Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1”, Journal of General Virology 90 (11):  2622–2633, http://vir.sgmjournals.org/cgi/content/full/90/11/2622 2009年11月4日閲覧。
1 2  Manno CS, Pierce GF, Arruda VR, et al. (March 2006). “Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response”. Nature Medicine 12 (3):  342–7. doi:10.1038/nm1358. PMID 16474400.
↑  Sabatino DE, Mingozzi F, Hui DJ, et al. (December 2005). “Identification of mouse AAV capsid-specific CD8+ T cell epitopes”. Molecular Therapy 12 (6):  1023–33. doi:10.1016/j.ymthe.2005.09.009. PMID 16263332.
1 2  Matsushita T, Elliger S, Elliger C, et al. (July 1998). “Adeno-associated virus vectors can be efficiently produced without helper virus”. Gene Therapy 5 (7):  938–45. doi:10.1038/sj.gt.3300680. PMID 9813665.
↑  Myers MW, Laughlin CA, Jay FT, Carter BJ (July 1, 1980). “Adenovirus helper function for growth of adeno-associated virus: effect of temperature-sensitive mutations in adenovirus early gene region 2”. Journal of Virology 35 (1):  65–75. PMC 288783. PMID 6251278. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=6251278.
↑  Handa H, Carter BJ (July 25, 1979). “Adeno-associated virus DNA replication complexes in herpes simplex virus or adenovirus-infected cells”. The Journal of Biological Chemistry 254 (14):  6603–10. PMID 221504. http://www.jbc.org/cgi/pmidlookup?view=long&pmid=221504.
↑  Yalkinoglu AO, Heilbronn R, Bürkle A, Schlehofer JR, zur Hausen H (June 1, 1988). “DNA amplification of adeno-associated virus as a response to cellular genotoxic stress”. Cancer Research 48 (11):  3123–9. PMID 2835153. http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=2835153.
↑  Yakobson B, Koch T, Winocour E (April 1, 1987). “Replication of adeno-associated virus in synchronized cells without the addition of a helper virus”. Journal of Virology 61 (4):  972–81. PMC 254052. PMID 3029431. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=3029431.
↑  Yakobson B, Hrynko TA, Peak MJ, Winocour E (March 1, 1989). “Replication of adeno-associated virus in cells irradiated with UV light at 254 nm”. Journal of Virology 63 (3):  1023–30. PMC 247794. PMID 2536816. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=2536816.
↑  Duan D, Sharma P, Yang J, et al. (November 1, 1998). “Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue”. Journal of Virology 72 (11):  8568–77. PMC 110267. PMID 9765395. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=9765395.